370
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs

ORCID Icon, , , , , , , , , & show all
Pages 599-605 | Received 11 Jul 2017, Accepted 12 Sep 2017, Published online: 03 Oct 2017

References

  • Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(9):1233–38.
  • Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the rising study. Mod Rheumatol. 2009;19(5):478–87.
  • Ootomo K, Kurita T, Odani T, Fujieda Y, Kato M, Kon Y, et al. The efficacy of treating according to a dose-escalation infliximab increasing protocol. The practice of Treat to Target (T2T) aimed at the low disease activity (in Japanese). Clin Rheumatol Rel Res. 2012;24:118–24.
  • Toshihiko H, Yayoi H, Eiko N, Yasufumi K, Hiroshi K, Keiich M. Effectiveness of infliximab dose escalation therapy in patients with rheumatoid arthritis in accordance with a protocol- Possibility of reduction or discontinuation of infliximab after dose escalation therapy in daily clinical practice (in Japanese). Clin Rheumatol Rel Res. 2016;28:260–70.
  • Daisuke K, Satoshi I, Megumi U, Asami A, Hiroshi O, Hajime I, et al. Effectiveness of infliximab for rheumatoid arthritis with dose escalation and shortened dosing interval. Clin Rheumatol Rel Res. 2017;29:12–21.
  • Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol. 2002;29:667–77.
  • Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
  • Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.
  • Oh K, Ito S, Unno M, Kobayashi D, Azuma C, Abe A, et al. The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate. Intern Med. 2015;54(9):1035–41.
  • Ito S, Unno M, Kobayashi D, Oh K, Otani H, Abe A, et al. Dose escalation of methotrexate in rheumatoid arthritis patients. J New Rem Clin. 2014;63:1302–15.
  • Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
  • Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–88.
  • Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000;43(1):22–29.
  • Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45(12):1558–65.
  • Curtis JR, Yang S, Chen L, Park GS, Bitman B, Wang B, et al. Predicting low disease activity and remission using early treatment response to antitumor necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2012;71(2):206–12.
  • Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multi-center, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis, and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096–103.
  • Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomized, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–50.
  • Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94.
  • Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomized EXXELERATE study. Lancet. 2016;388(10061):2763–74.
  • Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, et al. The effectiveness and medication costs of three anti-tumor necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2007;67(9):1229–34.
  • Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32.
  • Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept, and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012;71(7):1134–42.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.